Toronto Stock Exchange Symbol: MS
EDMONTON, Nov. 14 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the third quarter, ended September 30, 2007.
"During the quarter, we continued to maintain momentum towards the commercialization of our lead drug, MBP8298, for the treatment of multiple sclerosis," said Kevin Giese, President and CEO of BioMS Medical.
Third Quarter 2007 Highlights:
- The independent Data Safety Monitoring Board (DSMB) for MINDSET-01,
the Company's on-going phase II trial of MBP8298 for relapsing-
remitting MS, completed a safety analysis and recommended that the
trial continue as per protocol. This double blind phase of this trial
is expected to complete in the second half of 2008.
- Subsequent to the end of the quarter,
- Two posters presented at the 23rd Congress of the European
Committee for Treatment and Research in Multiple Sclerosis
(ECTRIMS) in Prague, Czech Republic, in respect of the phase
III MAESTRO-01 secondary progressive MS (SPMS) study, showed
that over 70% of the screened patients had the drug's target
HLA DR2 and/or DR4 responder genes, and that an interim
analysis showed no significant safety concerns with the drug.
An interim safety and efficacy analysis for MAESTRO-01 is
planned for mid-2008.
- The Company announced that the U.S. pivotal phase III SPMS
trial, MAESTRO-03, is on track for full enrollment in 2008, and
completed enrollment of the first 133 patients who will form
the basis of an interim analysis that is expected in 2009.
The consolidated net loss for the three months ended
|SOURCE BioMS Medical Corp.|
Copyright©2007 PR Newswire.
All rights reserved